News Related to Critical Temperature Threshold

Related coverage linked through entity extraction aliases.

Novartis Remibrutinib Achieves Phase III Endpoint in Chronic Inducible Urticaria

Feb 18, 2026

Novartis reported positive Phase III RemIND trial results showing remibrutinib achieved complete response in three types of chronic inducible urticaria. The company has submitted a supplemental New Drug Application to the FDA for symptomatic dermographism.

Novartis Remibrutinib Meets Phase III Endpoint in Chronic Inducible Urticaria

Feb 18, 2026

Novartis announced positive Phase III RemIND trial results for oral remibrutinib in chronic inducible urticaria, marking the first therapy to meet a Phase III primary endpoint in the condition. The company has submitted a supplemental New Drug Application to the FDA.